Therapy of allergic bronchial asthma with omalizumab – an anti-IgE monoclonal antibody

Bibliography

• EUROPEAN COMMUNITYRESPIRATORY HEALTH SURVEY: Variations in the prevalence of respiratory symptoms, self-reported asthma attacks and the use of asthma medications in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. (1996) 9:687–695.
   PubMed Web of Science ®Google Scholar
• WOOLCOCK AJ, PEAT JK: Evidence for the increase in asthma worldwide. In: The rising trend M asthma. Ciba Foundation Symposium 206, John Wiley & Sons, Chichester (1997):122–139.
   Google Scholar
• THE INTERNATIONAL STUDY OF ASTHMA AND ALLERGY IN CHILDHOOD (ISAAC) STEERING COMMITTEE: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet (1998) 351:1225–1232.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST: The cellular and mediator basis of asthma in relation to natural history. Lancet (1997) 350(Suppl. II):5–9.
   Google Scholar
• D'AMATO G, HOLGATE ST: The impact of air pollution on respiratory health.D'Amato G & Holgate ST (Eds), European Respiratory Monograph n.21, Sheffield, UK (2002).
   Google Scholar
• BOUSQUET J, CHANEZ P,LACOSTE JY et al: Eosinophilic inflammation in asthma. N Engl. I Med.(1990) 323:1033–1039.
   PubMed Web of Science ®Google Scholar
• BUSSE WW, COFFMAN RL, GELFAND EW, KAY AB, ROSENWASSER LJ: Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. kn. Respir. Grit. Care Med. (1995) 152:388–393.
   PubMed Web of Science ®Google Scholar
• PRESTA LG, LAHR SJ, SHIELDS RL et al.: Humanization of an antibody directed against IgE. Immunol (1993) 151:2623–2632.
   Web of Science ®Google Scholar
• LIU J, LESTER P, BUILDERS, SHIRE SJ:Characterization of complex formation by humanized anti-IgE antibody and monoclonal IgE. Biochemistry (1995) 34:10474–10482.
   PubMed Web of Science ®Google Scholar
• MACGLASHAN DW, BOCHNER BS, ADELMAN DC et al: Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. Immunol (1997) 158:1438–1445.
   Web of Science ®Google Scholar
• BOULET L-P, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced earlyasthmatic response. Am. Respir. Crit. Care Med. (1997) 155:1835–1840.
   PubMed Web of Science ®Google Scholar
• FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. (1997) 155:1828–1834.
   PubMed Web of Science ®Google Scholar
• CASALE TB, BERNSTEIN IL, BUSSE WW et al.: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. I Allergy Clin.Immunol. (1997) 100:110–121.
   PubMed Web of Science ®Google Scholar
• TOGIAS A, CORREN J, SHAPIRO G et al.: Anti-IgE treatment reduces skin test (ST) reactivity. I Allergy Clin. Immunol (1998) 101:S171.
   PubMed Web of Science ®Google Scholar
• CASALE T, CONDEMI J, MILLER SD et al.: rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR). Ann. Allergy Asthma Immunol (1999) 82:75.
   Web of Science ®Google Scholar
• ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. Allergy Clin. Immunol (2000) 106(2):253–259.
   Google Scholar
• FAHY JV: The anti-IgE treatment strategy for asthma. In: New, and Exploratory Therapeutic Agents for Asthma: Lung BiologyM Health and Disease, Yeadon M,Diamant Z (Eds), Marcel Dekker, Inc., NY (2000):329–342.
   Google Scholar
• BUHL R, SOLER M, MATZ J et aL: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Ear: Respir (2002) 20:73–78.
   PubMed Web of Science ®Google Scholar
• BUHL R, HANF G, SOLER M et al: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Ear: Respir. .1. (2002) 20:1088-1094.
   Google Scholar
• HOLGATE S, BOUSQUET J,WENZEL S, FOX H, LIU J, CASTELLSAGUE J: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr: Med. Res. Opin. (2001) 17:233–240.
   PubMed Web of Science ®Google Scholar
• MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108(2):36–45.
   PubMed Web of Science ®Google Scholar
• SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement inallergic asthmatics. Ear: Respir. (2001) 18:254–261.
   PubMed Web of Science ®Google Scholar
• BUSSE W, COREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.' Allergy Clin. Immunol (2001) 108:184–190.
   PubMed Web of Science ®Google Scholar
• D'AMATO G: Treating atopic asthma with the anti-IgE monoclonal antibody. Monaldi Arch. Chest Dis. (2002) 57(2):117–119.
   Google Scholar
• PLEWAKO H, ARVIDSSON M, PETRUSON K et al.: The effect of omalizumab on nasal allergic inflammation. Allergy Clin. Immunol. (2002) 110:68–71.
   Google Scholar
• KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. I Allergy Clin. Immunol (2002) 109:274–280.
   PubMed Web of Science ®Google Scholar
• KOPP MV, BRAUBURGER J, RIEDINGER F et al.: The effect of anti-IgE treatment on M vitro leukotriene release in children with seasonal allergic rhinitis. Allergy Clin. Immunol (2002) 110:728–735.
   Google Scholar
• ISHIZAKA K, ISHIZAKA T: Physicochemical properties of reaginic antibodies. I. Association of reaginic activity with an immunoglobulin other than gamma A or gamma G globulin.' Allergy (1966) 37:169–173.
   Google Scholar
• JOHANSSON SGO, BENNICH H: Immunological studies of an atypical (myeloma) immunoglobulin. Immunology (1967) 13:381–384.
   PubMed Web of Science ®Google Scholar